Skip to content

Released May 10, 2022, before the open

10-Q filed May 10, 2022, 40 days after period end · 0001785530-22-000021

Q1 2022 · 10-Q
Revenue—
Net Income-$15.34MN/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.56N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$15,366,000N/M
Operating Cash Flow-$13,951,000N/M
Free Cash Flowderived-$13,979,000N/M

What the release said

The release

Same quarter

MetricQ1 2022Q1 2021Q1 2020
Net Income-$15.34M-$7.44M-$3.83M
EPS Diluted-$0.56-$83.36-$4.58

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR